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Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia. Although known as a distinct entity for
a very long time, because of lack of distinct clinical features and morphological criteria, it is diﬃcult to diagnose this variant
correctly. We herein present the clinical, morphological, cytochemical, and immunocytochemical features of ﬁve cases of AMKL.
Certain morphological features such as presence of abnormal platelet count, giant platelets, and cytoplasmic blebbing in blasts
were found to be important pointers towards the diagnosis. However, none of the features were found to be consistent and thus
morphological diagnosis has to be conﬁrmed by cytochemistry and immunocytochemistry.
Copyright © 2009 Sunita Sharma et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Acute megakaryoblastic leukemia (AMKL) is a rare entity
and accounts for 3–5% of all acute myeloid leukemia [1].
Although described in literature for more than 70 years
[2], the clinical proﬁle and morphological criteria for its
diagnosis remain ill deﬁned. It can be confused with acute
lymphoblastic leukemia ALL-L1/acute myeloid leukemia
AML-M0. It may arise de novo or may be secondary to
chemotherapy, or progress from myeloproliferative neo-
plasm (MPN) and/or myelodysplastic syndrome [1, 3–5]. It
has a bimodal peak of distribution (in adults and children
1-2 years of age). Children with Down’s syndrome have a
particularly higher incidence of AMKL [6]. Here we describe
ﬁve cases of AMKL with variable clinicohaematological
presentations and discuss the diagnostic diﬃculties faced in
arriving at a deﬁnitive diagnosis.
2.MaterialsandMethods
All acute megakaryoblastic leukemias diagnosed in the
Department of Pathology of Lady Hardinge Medical College,
New Delhi, in the period 1997 to 2007, were included in the
study. A total of ﬁve cases were retrieved. The clinical history
and other details were taken from the case ﬁles.
Wright’s stained peripheral smears and bone marrow
aspirate (BMA) smears were examined. Bone marrow biopsy
was available in only one case.
Cytochemistry, including myeloperoxidase (MPO),
Sudan black B (SBB), periodic acid Schiﬀ (PAS), and
nonspeciﬁc esterase (NSE), was available in all the cases.
Immunophenotyping was done in 4 out of 5 cases. In 3/4
cases, immunocytochemistry was done by APAAP technique
usingDAKOantibodies(Figure 3)andinthefourthcaseﬂow
cytometry results were available.
3. Results
Clinical and haematological proﬁles of our 5 cases are
summarized in Tables 1 and 2.
Most of the cases were males (M:F = 4:1). Out of the
5 cases, two were adults while the other three were in the
pediatric age group (1.5 years to 6 years).
Four out of the ﬁve cases had an acute onset illness and
presented with symptoms of marrow inﬁltration while the
ﬁfth patient had a long history of 3 years duration which is
described separately.
One patient out of these 4 cases had features suggestive
of Down’s syndrome (Case IV). Hepatosplenomegaly and2 Advances in Hematology
Table 1: Clinical features and hematological parameters.
Features Case I Case II Case III Case IV Case V
Age/sex 6 years/M 20 years/F 1.5 years/M 2 years/M 22 years/M
C/F Pallor, easy
bruisability
Pallor, dyspnea,
gum bleeds, ma-
lena, hemateme-
sis
Fever, petechiae Fever, epistaxis,
seizures
Fever
Down’s syndrome ———+ —
Hepatomegaly +— +— +
Splenomegaly +— +— +
Lymphadenopathy ——+ — —
Hb (g/dL) 10.7 4.9 4.8 5.1 9.4
WBC (×109/L) 40 30 17.5 7.1 7.9
Plt count (×109/L) 30 480 14 60 203
Figure 1: Megakaryoblast with cytoplasmic blebbing (1000X).
lymphadenopathy were observed in two and one patient,
respectively (Table 1).
A l lt h ef o u rc a s e sw e r ea n e m i c .L e u c o c y t o s i sw a sn o t e d
in 3 while one case showed thrombocytosis (Case II). Giant
platelets were present in Case I only.
Peripheral blood blast count was in the range of 4% to
40%. The blasts were large, 3-4 times the size of a small
mature lymphocyte with moderate to abundant agranular
basophiliccytoplasm.Thenucleiwereroundtoovalwithﬁne
to stippled chromatin & 1-2 prominent nucleoli. Few blasts
in all the cases showed cytoplasmic blebbing (Figure 1).
Platelet budding was observed in 3/4 cases (Figure 2).
Bone marrow aspirate smears were cellular in three
out of four cases showing blasts ranging from 25% to
56% of all nucleated cells with morphology similar to
that seen in the peripheral blood along with presence of
micromegakaryocytes and promegakaryocytes. In one of the
cases, blasts showed clustering mimicking metastases (Case
I). In the fourth case (Case IV), repeated attempts of BMA
yielded diluted marrow. Bone marrow biopsy in this case
showed blasts with clustering and increased reticulin ﬁbers
(Grade III).
The ﬁfth case (Case V) had a long duration illness and
presented with weakness and abdominal distension for 3
years.
Figure 2: Megakaryoblast with platelet budding (1000X).
Figure 3: CD61 positivity in blast (200X).
Thispatienthadmassivesplenomegaly,7cmbelowcostal
margin and mild hepatomegaly. The patient was anemic
with a normal total leukocyte count and platelet count.
Peripheral smear showed a leukoerythroblastic blood picture
withpresenceofteardropcellsand25%blasts.Bonemarrow
aspirate revealed 28% blasts. These blasts had morphology
and cytochemical ﬁndings similar to those of the other
cases (Table 2). Based on these ﬁndings, a diagnosis of acute
megakaryoblastic leukemia arising as acute transformation
of myeloproliferative neoplasm (primary myeloﬁbrosis) was
made. Bone marrow biopsy and immunophenotyping was
suggested. However, the patient left against medical advice
and was lost to follow up.Advances in Hematology 3
Table 2: Morphology, cytochemistry and immunocytochemistry.
Case I Case II Case III Case IV Case V
Morphology
Peripheral smear
∗ Red cells
Normocytic
Normochromic Present Present Present Present Present with
tear drop cells
∗Blasts (%) 18% 40% 4% 5% 25%
∗Blast morphology
(i) agranular blue
cytoplasm with cy-
toplasmic blebbing
Present Present Present
Present (some
blasts were
granular)
Present
(ii) Giant platelets Present Absent Absent Absent Present
(iii) Platelet budding Present Present Absent Absent Present
Bone marrow
aspiration/biopsy
∗Hypercellular
marrow showing
megakaryoblasts,
micromegakary-
ocytes, promega-
karyocytes (full
range of diﬀeren-
tiation)
Present with
clustering
mimicking
metastasis
Present Present
Diluted BMA &
Biopsy showed
blasts with clus-
tering and incre-
ased reticulin ﬁbres
Present
∗Blast (%) 25% 45% 56% 25% (biopsy) 28%
Cytochemistry
PAS Positive Positive Negative Positive Positive
NSE
Positive,
ﬂuoride
resistant
Positive,
ﬂuoride
resistant
Positive,
ﬂuoride
resistant
Positive, ﬂuoride
resistant
Positive,
ﬂuoride
resistant
MPO/SBB Negative Negative Negative Negative Negative
Immunocytochemistry
Lymphoid markers
(CD5, 7,19, 20) Negative Negative Negative Negative Negative
Myeloid markers
(CD13,33) Negative Negative Negative Negative Equivocal
CD61 (Gp Illa) Positive Positive Positive Positive ND
4. Discussion
AMKLisarareleukemia,accountingfor7–10%ofchildhood
AML [7] and 1-2% of adult AML [8, 9] and confers a
poor prognosis. Patients with Down’s syndrome have an
increased incidence of AMKL and have a good prognosis
[6, 10]. AMKL can arise de novo or as a secondary event
post chemotherapy or progress from myeloproliferative
neoplasm or myelodysplastic syndrome [1, 3–5]. In our
study, one patient was possibly secondary to MPN (primary
myeloﬁbrosis).
It is diﬃcult to diagnose this variant solely on the basis
of morphology. However, there are features like clustering of
blasts, presence of cytoplasmic blebbing, and platelet bud-
ding which may be useful in clinching the diagnosis [7]. In
our study these features were present in majority of the cases
thus emphasizing their importance. Cytochemistry is not
very helpful although necessary to rule out other leukemias.
Bone marrow ﬁbrosis if present is a very important feature
and is seen in a high proportion of cases [6]. In a study
conducted at M. D. Anderson Cancer Centre including 37
cases of AMKL, bone marrow ﬁbrosis was present in 62%
of the cases [11], although in our study, bone marrow
biopsy was available in only one case which showed ﬁbrosis.
Immunophenotyping is necessary to conﬁrm the diagnosis
which could be performed in 4 out of the 5 cases.4 Advances in Hematology
Thrombocytosis was present in one patient who was
a 22-year-old female while the other adult patient had a
normal platelet count. All the three pediatric patients were
thrombocytopenic. This observation is similar tothatseen in
other studies [12], thus emphasizing the fact that AMKL can
be categorized as either undiﬀerentiated or diﬀerentiated,
with more diﬀerentiated ones occurring in adults [13].
5. Conclusion
AMKL is a rare leukemia. It is important to correctly
diagnose this variant in view of its prognostic implications.
Although immunophenotyping is the gold standard, it is
not available in all the centers. Careful search for features
like cytoplasmic blebbing, platelet budding, bone marrow
ﬁbrosis, clustering of blasts, and cytochemical positivity for
nonspeciﬁc esterase which is ﬂuoride resistant can help in
correctly diagnosing a signiﬁcant number of AMKL.
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